Boothbay Fund Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Boothbay Fund Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-263,800	Closed	-$1.89M	–	2210
2025 Q3	$1.89M	Buy	263,800 +192,900	+272%	+$10.1M	0.03%	591
2025 Q2	$3.35M	Buy	70,900 +42,400	+149%	+$1.73M	0.07%	388
2025 Q1	$1.11M	Buy	+28,500	New	+$1.23M	0.03%	592
2024 Q2	–	Sell	-42,000	Closed	-$2.11M	–	1742
2024 Q1	$2.11M	Sell	42,000 -8,000	-16%	-$434K	0.04%	486
2023 Q4	$3.02M	Buy	+50,000	New	+$2.58M	0.08%	359

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boothbay Fund Management's MLTX Position: Q4 2025 in Review

Boothbay Fund Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 258,779 shares — an estimated $1.86M sold.

Boothbay Fund Management first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $1.86M in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Boothbay Fund Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 258,779 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $1.86M.
Boothbay Fund Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
Boothbay Fund Management's MoonLake Immunotherapeutics position peaked at $1.86M in Q3 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.